JAMA Netw Open

Automated insulin delivery shows promise in patients with T2DM

February 21, 2025

Study details: This nonrandomized clinical trial included 305 adults with T2DM who were treated with insulin, with or without other glucose-lowering medications. Participants used an automated insulin delivery (AID) system for 13 weeks, and their HbA1c levels were monitored to assess changes in glycemic control.

Results: The study found a significant reduction in HbA1c levels, from 8.2% to 7.4%, representing a 0.8-percentage point decrease after 13 weeks of AID use. The cohort was socioeconomically, racially, and ethnically diverse, enhancing the generalizability of the findings.

Clinical impact: The results suggest that AID systems can effectively improve glycemic control in adults with T2DM, potentially reducing the risk of diabetes-related complications.

Source:

Parker JC, et al; Omnipod 5 SECURE-T2D Consortium. (2025, February 14). JAMA Netw Open. Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39951268/